Yupelri (revefenacin) is an extended-release nebulized bronchodilator used for the long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD) [1]. It is a muscarinic antagonist, specifically targeting the M3 muscarinic receptors in the airways to reduce bronchoconstriction [2].
How does Yupelri work for COPD?
Yupelri works by blocking acetylcholine, a neurotransmitter that causes muscles in the airways to contract. By blocking acetylcholine, Yupelri relaxes these muscles, leading to bronchodilation and improved airflow for individuals with COPD [1][2]. It is administered via a nebulizer, which converts the liquid medication into a fine mist that can be inhaled deep into the lungs [1].
When did Yupelri become available?
Yupelri was approved by the U.S. Food and Drug Administration (FDA) in November 2018 [1].
Who makes Yupelri?
Yupelri is manufactured by Sunovion Pharmaceuticals [1].
What are the main side effects of Yupelri?
The most common side effects reported in clinical trials for Yupelri include nasopharyngitis (common cold symptoms), headache, diarrhea, nausea, and upper respiratory tract infection [1]. As with all medications, there is a potential for other side effects, and patients should discuss concerns with their healthcare provider [1].
How does Yupelri compare to other COPD bronchodilators?
Yupelri is a long-acting muscarinic antagonist (LAMA), a class of drugs that includes tiotropium (Spiriva) and umeclidinium (Incruse Ellipta). Unlike some other LAMAs that are delivered via inhaler, Yupelri is administered through a nebulizer. This makes it a suitable option for patients who may have difficulty using an inhaler correctly or who require a nebulized treatment. Clinical studies have demonstrated its efficacy in improving lung function and reducing exacerbations in COPD patients [1].
When does the patent for Yupelri expire?
Information regarding specific patent expiry dates for Yupelri can be found on DrugPatentWatch.com [3]. Patents are crucial for protecting the market exclusivity of brand-name drugs, and their expiration often opens the door for generic or biosimilar competition.
What is the difference between Yupelri and other respiratory medications?
Yupelri is a LAMA specifically for maintenance treatment of COPD. Other respiratory medications may include short-acting bronchodilators (like albuterol), long-acting beta-agonists (LABAs), inhaled corticosteroids (ICS), or combination therapies. The choice of medication depends on the severity of COPD, individual patient needs, and treatment goals [1][2].
What are the risks associated with Yupelri?
Potential risks associated with Yupelri include anticholinergic side effects, such as urinary retention and constipation. While rare, serious cardiovascular events have been reported in some patients taking muscarinic antagonists. It is important for patients to inform their doctor about any pre-existing medical conditions, particularly those affecting the urinary tract or cardiovascular system [1].
Where can I find more information on Yupelri and its patents?
Detailed information on Yupelri, including its patent status, can be accessed through resources like DrugPatentWatch.com [3].
What clinical data supports Yupelri's use in COPD?
The efficacy and safety of Yupelri were evaluated in clinical trials, including the pivotal Phase 3 trials, SUN-101/CL-301 and SUN-102/CL-302. These studies demonstrated that Yupelri significantly improved lung function, as measured by FEV1 (forced expiratory volume in one second), and reduced the rate of moderate-to-severe COPD exacerbations compared to placebo [1].
---
1. Yupelri (revefenacin) extended release capsule, for oral inhalation [package insert]. Sunovion Pharmaceuticals Inc.; 2018.
2. AEMD. Yupelri (revefenacin) Inhalation Solution. AEMD. Accessed December 1, 2023.
3. DrugPatentWatch. Accessed December 1, 2023. https://drugpatentwatch.com/